Protective effects of vasonatrin peptide against hypobaric hypoxia-induced pulmonary hypertension in rats

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 1, 2010, Pages 69-74

  Yu, Jun ^a   Feng, Hua Song ^b   Chen, Bao Ying ^c   Qu, Ping ^a   Liu, Li Bing ^a   Chen, Jian Kang ^a   Tie, Ru ^a   Huang, Xiao Jun ^a   Zhao, Yu Feng ^d   Zhu, Xiao Xing ^d   Zhu, Miao Zhang ^d  

^a School of Medical Sciences   (China)

^b NAVY GENERAL HOSPITAL   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^d FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Hypoxia; Natriuretic peptides; Pulmonary hypertension

Indexed keywords

ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN 1; MESSENGER RNA; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE RECEPTOR C; UNCLASSIFIED DRUG; VASONATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART RIGHT VENTRICLE; HEART RIGHT VENTRICLE HYPERTROPHY; HEART VENTRICLE HYPERTROPHY; HYPOBARISM; HYPOXIA; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; NONHUMAN; PROTEIN BLOOD LEVEL; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT;

ANGIOTENSIN II; ANIMALS; ANOXIA; ANTIHYPERTENSIVE AGENTS; ATMOSPHERIC PRESSURE; ATRIAL NATRIURETIC FACTOR; DISEASE MODELS, ANIMAL; ENDOTHELIN-1; HEART VENTRICLES; HEMODYNAMICS; HYPERTENSION, PULMONARY; HYPERTROPHY, RIGHT VENTRICULAR; MALE; PULMONARY ARTERY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 74049148597     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2009.05240.x     Document Type: Article

References (40)

1. Penaloza D, Arias-Stella J. The heart and pulmonary circulation at high altitudes. Healthy highlanders and chronic mountain sickness. Circulation 2007 115 : 1132 1146.
2. Penaloza D, Sime F, Ruiz L. Pulmonary hemodynamics in children living at high altitudes. High Alt. Med. Biol. 2008 9 : 199 207.
3. Holt TN, Callan RJ. Pulmonary arterial pressure testing for high mountain disease in cattle. Vet. Clin. North Am. Food Anim. Pract. 2007 23 : 575 596.
4. Hainsworth R, Drinkhill MJ. Cardiovascular adjustments for life at high altitude. Respir. Physiol. Neurobiol. 2007 158 : 204 211.
5. Preston IR. Clinical perspective of hypoxia-mediated pulmonary hypertension. Antioxid. Redox Signal. 2007 9 : 711 721.
6. Brion R. The heart and the mountains. Arch. Mal. Coeur Vaiss. 2006 99 : 1121 1125.
7. Tual L, Morel OE, Favret F et al. Carvedilol inhibits right ventricular hypertrophy induced by chronic hypobaric hypoxia. Pflügers Arch. 2006 452 : 371 379.
8. Kay JM, Suyama KL, Keane PM. Effect of intermittent normoxia on muscularization of pulmonary arterioles induced by chronic hypoxia in rats. Am. Rev. Respir. Dis. 1981 123 : 454 458.
9. Hislop A, Reid L. Changes in the pulmonary arteries of the rat during recovery from hypoxia-induced pulmonary hypertension. Br. J. Exp. Pathol. 1977 58 : 653 662.
10. Tuchscherer HA, Vanderpool RR, Chesler NC. Pulmonary vascular remodeling in isolated mouse lungs: Effects on pulsatile pressure-flow relationships. J. Biomech. 2007 40 : 993 1001.
11. Keith IM. The role of endogenous lung neuropeptides in regulation of the pulmonary circulation. Physiol. Res. 2000 49 : 519 537.
12. Hubloue I, Biarent D, Abdel Kafi S et al. Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction. Eur. Respir. J. 2003 21 : 19 24.
13. A receptor antagonist LU-135252 selectively attenuates hypoxic pulmonary vasoconstriction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008 294 : R601 5.
14. Ferreira AJ, Shenoy V, Yamazato Y et al. Evidence for angiotensin converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2009 179 : 1048 1054.
15. Leeman M, de Beyl VZ, Delcroix M, Naeije R. Effects of endogenous nitric oxide on pulmonary vascular tone in intact dogs. Am. J. Physiol. 1994 266 : H2343 7.
16. Pei JM, Sun X, Guo HT et al. U50,488H depresses pulmonary pressure in rats subjected to chronic hypoxia. J. Cardiovasc. Pharmacol. 2006 47 : 594 598.
17. Chen YF. Atrial natriuretic peptide in hypoxia. Peptides 2005 26 : 1068 1077.
18. Muramatsu M, Tyler RC, Gutkowska J et al. Atrial natriuretic peptide accounts for increased cGMP in hypoxia-induced hypertensive rat lungs. Am. J. Physiol. 1997 272 : L1126 32.
19. Klinger JR, Warburton RR, Pietras L, Hill NS. Brain natriuretic peptide inhibits hypoxic pulmonary hypertension in rats. J. Appl. Physiol. 1998 84 : 1646 1652. (Pubitemid 28225903)
20. Klinger JR, Siddiq FM, Swift RA et al. C-Type natriuretic peptide expression and pulmonary vasodilation in hypoxia-adapted rats. Am. J. Physiol. 1998 275 : L645 52.
21. Mitani Y, Maruyama J, Yokochi A et al. Modulated vasodilator responses to natriuretic peptides in rats exposed to chronic hypoxia. Eur. Respir. J. 2000 15 : 400 406.
22. Nakanishi K, Tajima F, Itoh H et al. Changes in atrial natriuretic peptide and brain natriuretic peptide associated with hypobaric hypoxia-induced pulmonary hypertension in rats. Virchows Arch. 2001 439 : 808 817.
23. Wei CM, Kim CH, Miller VM, Burnett JC Jr. Vasonatrin peptide: A unique synthetic natriuretic and vasorelaxing peptide. J. Clin. Invest. 1993 92 : 2048 2052.
24. Morishita Y, Sano T, Ando K et al. Microbial polysaccharide, HS-142-1, competitively and selectively inhibits ANP binding to its guanylyl cyclase-containing receptor. Biochem. Biophys. Res. Commun. 1991 176 : 949 957.
25. Misono KS. Natriuretic peptide receptor: Structure and signaling. Mol. Cell. Biochem. 2002 230 : 49 60.
26. Sun JZ, Chen SJ, Li G, Chen YF. Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000 279 : L511 9.
27. Li H, Oparil S, Meng QC, Elton TS, Chen YF. Selective downregulation of ANP-clearance-receptor gene expression in lung of rats adapted to hypoxia. Am. J. Physiol. 1995 268 : L328 35.
28. Andreassi MG, Del Ry S, Palmieri C, Clerico A, Biagini A, Giannessi D. Up-regulation of 'clearance' receptors in patients with chronic heart failure: A possible explanation for the resistance to biological effects of cardiac natriuretic hormones. Eur. J. Heart Fail. 2001 3 : 407 414.
29. Kim SZ, Cho KW, Kim SH. Modulation of endocardial natriuretic peptide receptors in right ventricular hypertrophy. Am. J. Physiol. 1999 277 : H2280 9.
30. Klinger JR, Arnal F, Warburton RR, Ou LC, Hill NS. Downregulation of pulmonary atrial natriuretic peptide receptors in rats exposed to chronic hypoxia. J. Appl. Physiol. 1994 77 : 1309 1316.
31. Feng HS, Zang YM, Zhu MZ et al. Comparison of vasorelaxing actions of vasonatrin peptide, C-type natriuretic peptide and atrial natriuretic peptide. Sheng Li Xue Bao 1999 51 : 515 520 (in Chinese with an English abstract).
32. Lu SY, Wang DS, Zhu MZ, Zhang QH, Hu YZ, Pei JM. Inhibition of hypoxia-induced proliferation and collagen synthesis by vasonatrin peptide in cultured rat pulmonary artery smooth muscle cells. Life Sci. 2005 77 : 28 38.
33. Lu SY, Zhu MZ, Guo HT, Yu J, Wei QM. Inhibition of moderate hypoxia-induced protein synthesis by vasonatrin peptide in cultured neonatal rat cardiomyocytes. Sheng Li Xue Bao 2002 54 : 7 11 (in Chinese with an English abstract).
34. Lu SY, Zhu MZ, Wang DS et al. Down-regulation of C-type natriuretic peptide receptor by vasonatrin peptide in cardiac myocytes and fibroblasts. Acta Pharmacol. Sin. 2004 25 : 424 430.
35. Michelakis ED, McMurtry MS, Wu XC et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: Role of increased expression and activity of voltage-gated potassium channels. Circulation 2002 105 : 244 250.
36. Itoh T, Nagaya N, Murakami S et al. C-Type natriuretic peptide ameliorates monocrotaline-induced pulmonary hypertension in rats. Am. J. Respir. Crit. Care Med. 2004 170 : 1204 1211. (Pubitemid 39577379)
37. Yu J, Zhu MZ, Wei GZ et al. Vasorelaxing role of vasonatrin peptide in human intramammary artery in vitro. Sheng Li Xue Bao 2003 55 : 187 190 (in Chinese with an English abstract).
38. Wei CM, Kim CH, Khraibi AA, Miller VM, Burnett JC Jr. Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. Hypertension 1994 23 : 903 907.
39. Dong MQ, Zhu MZ, Yu J, Shang LJ, Feng HS. Comparison of inhibitory effects of three natriuretic peptides on the proliferation of pulmonary artery smooth muscle cells of rats. Sheng Li Xue Bao 2000 52 : 252 254 (in Chinese with an English abstract).
40. Lu SY, Zhu MZ, Wang DS et al. Inhibition of the proliferation of smooth muscle cells from human coronary bypass vessels by vasonatrin peptide. Physiol. Res. 2004 53 : 387 393.